Earnings Call Summary | Milestone Scientific(MLSS.US) Q1 2024 Earnings Conference
Earnings Call Summary | Milestone Scientific(MLSS.US) Q1 2024 Earnings Conference
The following is a summary of the Milestone Scientific Inc. (MLSS) Q1 2024 Earnings Call Transcript:
以下是里程碑科學公司（MLSS）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Milestone Scientific recorded Q1 2024 revenue of $2.2 million, seeing a slight decrease compared to the same period last year due to a drop in international sales and a reserve reversal in Q1 2023.
E-commerce sales witnessed a year-on-year growth of 31%.
Shift to a direct sales model led to an increase in the gross margin, up to 74.5% in Q1 2024 from 72.7% the previous year.
The Dental division earned an operating income of approximately $625,000 for Q1 2024.
Despite the reduction in sales from $2.6 million to $2.2 million, and continued losses at $1.5 million per quarter, the company ensures sufficient liquid assets for operations.
里程碑科學錄得2024年第一季度收入爲220萬美元，與去年同期相比略有下降，這是由於國際銷售額下降和2023年第一季度儲備逆轉。
電子商務銷售額同比增長31％。
轉向直銷模式導致毛利率從上一年的72.7％提高到2024年第一季度的74.5％。
牙科部門在2024年第一季度的營業收入約爲62.5萬美元。
儘管銷售額從260萬美元下降至220萬美元，並且持續虧損爲每季度150萬美元，但該公司仍確保了足夠的流動資產用於運營。
Business Progress:
業務進展：
Launched a new online sales portal, transitioning from distributor-based relationships to a direct sales model in the US.
Established direct relationships with dental customers leading to potential recurring orders.
Interactive digital learning platform is in the works and sales to organizations like Meridian Endo Imperial and Main Dental Group have been recorded.
Expansion plans are in place for improvement in international markets, with new partnerships being formed.
Significant progress in Medical segment, especially on reimbursement for CompuFlo technology.
Ongoing negotiations with Medicare in the US, targeting the first two jurisdictions representing around 22% of all epidural steroid injections.
Continuing relationships and negotiations to further develop and promote patented technology in Europe and the US, especially for fields like anesthesia and peripheral nerve block.
Innovation found applications in neurosurgery, enhancing efficiency and safety of spinal cord stimulation procedures.
推出了一個新的在線銷售門戶，在美國從基於分銷商的關係過渡到直銷模式。
與牙科客戶建立了直接關係，導致了潛在的重複訂單。
交互式數字學習平台正在建設中，已記錄了對Meridian Endo Imperial和Main Dental Group等組織的銷售。
爲了改善國際市場，已經制定了擴張計劃，並正在建立新的合作伙伴關係。
醫療領域取得了重大進展，尤其是在CompuFLO技術的報銷方面。
正在與美國Medicare進行談判，目標是前兩個司法管轄區，約佔所有硬膜外類固醇注射的22％。
繼續保持關係和談判，以進一步開發和推廣歐洲和美國的專利技術，特別是在麻醉和周圍神經阻滯等領域。
創新在神經外科中得到了應用，提高了脊髓刺激手術的效率和安全性。
More details: Milestone Scientific IR
更多詳情： 里程碑科學紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。